These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29562340)

  • 1. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; Tomaselli S; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 May; 73(5):1305-1313. PubMed ID: 29562340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP
    Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Bowker KE; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
    Sutherland CA; Verastegui JE; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
    Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Blondeau JM; Blondeau LD; Fitch SD
    J Chemother; 2024 Sep; 36(5):389-397. PubMed ID: 38339845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; Tomaselli S; MacGowan AP
    J Antimicrob Chemother; 2016 May; 71(5):1270-8. PubMed ID: 26846209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system.
    Ghazi IM; Grupper M; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):2. PubMed ID: 28095918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints.
    Tsala M; Vourli S; Georgiou PC; Pournaras S; Tsakris A; Daikos GL; Mouton JW; Meletiadis J
    J Antimicrob Chemother; 2018 Apr; 73(4):953-961. PubMed ID: 29377998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Gill CM; Nicolau DP
    Antimicrob Agents Chemother; 2023 May; 67(5):e0173822. PubMed ID: 37022170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
    Ghazi IM; Grupper M; Nicolau DP
    Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; MacGowan AP
    J Antimicrob Chemother; 2021 Jun; 76(7):1840-1844. PubMed ID: 33975336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models.
    van der Meijden A; Aranzana-Climent V; van der Spek H; de Winter BCM; Couet W; Meletiadis J; Muller AE; van den Berg S
    J Antimicrob Chemother; 2023 Mar; 78(3):832-839. PubMed ID: 36718051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii.
    Noel AR; Attwood M; Bowker KE; MacGowan AP
    J Antimicrob Chemother; 2021 Feb; 76(3):667-670. PubMed ID: 33294925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa.
    Heffernan AJ; Sime FB; Naicker S; Andrews K; Ellwood D; Guerra-Valero Y; Wallis S; Lipman J; Grimwood K; Roberts JA
    Diagn Microbiol Infect Dis; 2021 Jun; 100(2):115329. PubMed ID: 33714790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.